Alameda, CA – According to filings with the U.S. Securities and Exchange Commission, Scribe Therapeutics is raising $100,000,002.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Benjamin Oakes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Scribe Therapeutics

Scribe is molecular engineering. The most advanced platform for CRISPR-based genetic medicine. Our integrated technologies, designed to be the best for therapeutic use, offer key advantages. Delivery: Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Activity: Engineered novel, highly active editing activities capable of editing out the underlying causes of disease. Safety: Built for exceptional specificity within the genome enabling therapeutic precision and allele specific targeting. Positioning: Highly differentiated molecules for bypassing pre-existing immunity and additional challenges.

To learn more about Scribe Therapeutics, visit http://www.scribetx.com/

Contact:
Benjamin Oakes, Chief Executive Officer
510-454-0213
https://www.linkedin.com/in/benjamin-oakes-4b92a620/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved